NewKerala.com

NIPER Hajipur & Boehringer Ingelheim Sign MoU to Boost Pharma Research

NIPER Hajipur has signed an MoU with Boehringer Ingelheim India to strengthen industry-academia collaboration in pharmaceutical research. The partnership will provide researchers access to the opnMe® open science platform to accelerate healthcare innovation. It aims to build research capacity, offer hands-on training, and generate early-stage proof-of-concept data. The collaboration supports building a robust, innovation-driven healthcare ecosystem in India.

Key Points: NIPER Hajipur-Boehringer Ingelheim MoU for Pharma Research

  • NIPER Hajipur signs MoU with Boehringer Ingelheim
  • Partnership provides access to opnMe® platform
  • Aims to build research capacity and student training
  • Supports innovation-driven healthcare ecosystem
2 min read

NIPER Hajipur signs MoU with Boehringer Ingelheim to advance pharmaceutical research collaboration

NIPER Hajipur signs MoU with Boehringer Ingelheim to advance pharmaceutical research via opnMe platform, boosting academia-industry collaboration.

"academia-industry collaboration in bridging the gap between research and commercialisation and fostering innovation - Manoj Joshi"

New Delhi, April 24

The National Institute of Pharmaceutical Education and Research Hajipur on Friday signed a Memorandum of Understanding with Boehringer Ingelheim India Pvt. Ltd. to strengthen industry-academia collaboration and advance pharmaceutical research, according to an official release issued by the Ministry of Chemicals and Fertilisers.

The MoU was signed in the presence of Manoj Joshi, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers, at Kartavya Bhawan in New Delhi.

Under this partnership, Boehringer Ingelheim will provide researchers access to its opnMe® open science platform, enabling wider scientific exchange and accelerating healthcare innovation. The collaboration will build research capacity at NIPER Hajipur, provide students with hands-on training, and generate early-stage proof-of-concept data that can be scaled into preclinical development.

By harnessing a resource-efficient, integrated research framework, the partnership aims to translate scientific discoveries into viable therapies, positioning NIPER Hajipur as a leader in translational pharmacology.

Speaking on the occasion, Shri Manoj Joshi highlighted the pivotal role of academia-industry collaboration in bridging the gap between research and commercialisation and fostering innovation.

The collaboration between NIPER Hajipur and Boehringer Ingelheim is expected to foster synergy between academia and industry, contribute to the development of next-generation therapies, and support the broader objective of building a robust, innovation-driven healthcare ecosystem in the country.

- ANI

Share this article:

Reader Comments

P
Priya S
Good to see such partnerships happening, but I hope this translates into affordable medicines for the common man. Too often, these MoUs remain on paper. Let's see concrete outcomes like new drugs developed here rather than just imported later. Keeping my expectations realistic.
V
Vikram M
As a pharma professional, I can say this is a big deal. Boehringer Ingelheim is a top global player in areas like respiratory and oncology. If even a fraction of that expertise rubs off on NIPER students, our drug discovery ecosystem will benefit hugely. Kudos to the Department of Pharmaceuticals for facilitating this. 👏
R
Rohit P
Hope this isn't just another MoU signing ceremony for the photo op. We've seen countless such agreements, but the real test is how many students actually get hands-on training and how many new molecules come out. Still, better late than never. Let's see some results in the next 2-3 years.
A
Ananya R
So proud that a government institute like NIPER is partnering with a global giant. This will definitely put Bihar on the pharma map. But I sincerely hope our researchers get equal intellectual property rights and not just be used as cheap labor for foreign companies. Make in India should mean "Own in India" too.
M
Meera T
Excellent step towards translational pharmacology! As someone who has seen the gap between lab research and market, this partnership can actually help bridge that. The opnMe platform is fantastic for early-stage proof-of-concept studies. Just wish more such MoUs were signed with NIPERs across India. 🌟

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50